BR112022016359A2 - Formas cristalinas de um composto farmacêutico - Google Patents

Formas cristalinas de um composto farmacêutico

Info

Publication number
BR112022016359A2
BR112022016359A2 BR112022016359A BR112022016359A BR112022016359A2 BR 112022016359 A2 BR112022016359 A2 BR 112022016359A2 BR 112022016359 A BR112022016359 A BR 112022016359A BR 112022016359 A BR112022016359 A BR 112022016359A BR 112022016359 A2 BR112022016359 A2 BR 112022016359A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
pharmaceutical compound
compound
pharmaceutical
forms
Prior art date
Application number
BR112022016359A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Reader John
Conor Marshall Jamie
Mykytiuk John
Scott Northen Julian
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of BR112022016359A2 publication Critical patent/BR112022016359A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022016359A 2020-04-07 2021-04-06 Formas cristalinas de um composto farmacêutico BR112022016359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (1)

Publication Number Publication Date
BR112022016359A2 true BR112022016359A2 (pt) 2022-10-04

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016359A BR112022016359A2 (pt) 2020-04-07 2021-04-06 Formas cristalinas de um composto farmacêutico

Country Status (11)

Country Link
US (2) US12545652B2 (cg-RX-API-DMAC7.html)
EP (1) EP4132649A1 (cg-RX-API-DMAC7.html)
JP (1) JP7660135B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220164751A (cg-RX-API-DMAC7.html)
CN (1) CN115515683B (cg-RX-API-DMAC7.html)
BR (1) BR112022016359A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167172A1 (cg-RX-API-DMAC7.html)
GB (1) GB202005114D0 (cg-RX-API-DMAC7.html)
IL (1) IL296989A (cg-RX-API-DMAC7.html)
MX (1) MX2022011593A (cg-RX-API-DMAC7.html)
WO (1) WO2021204762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
JP2025510826A (ja) * 2022-03-25 2025-04-15 武田薬品工業株式会社 Tyk2阻害剤の固体形態及び使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG11201401342VA (en) 2011-10-12 2014-09-26 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
BR112016004723B1 (pt) * 2013-09-03 2022-08-30 Sareum Limited Compostos de pirrolidina ou morfolina e composição contendo os mesmos
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2021253128A1 (en) 2022-08-25
GB202005114D0 (en) 2020-05-20
KR20220164751A (ko) 2022-12-13
JP7660135B2 (ja) 2025-04-10
EP4132649A1 (en) 2023-02-15
MX2022011593A (es) 2022-10-18
CA3167172A1 (en) 2021-10-14
US20230159473A1 (en) 2023-05-25
IL296989A (en) 2022-12-01
CN115515683A (zh) 2022-12-23
WO2021204762A1 (en) 2021-10-14
CN115515683B (zh) 2024-10-25
US20260217664A1 (en) 2026-07-30
US12545652B2 (en) 2026-02-10
JP2023521631A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
CL2022003528A1 (es) Formas cristalinas novedosas (divisional de cl 202002056).
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
DOP2020000023A (es) Nuevos derivados de quinolina
MX2020007947A (es) Inhibidores de erbb/btk.
CO2020013876A2 (es) Nuevos derivados de quinolina
CO2023013469A2 (es) Derivados de fósforo como nuevos inhibidores de sos1
UY38716A (es) Derivados de isoxazolina herbicidamente activos, y procesos e intermediarios utilizados para la preparación de estos derivados
BR112022001125A2 (pt) Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CR20240408A (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
MX2022005522A (es) Formas de sal de un receptor de componente c5a de complemento.
ECSP034598A (es) Compuesto lactamico
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
ECSP22046595A (es) Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
MX2022011593A (es) Formas cristalinas de un compuesto farmaceutico.
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
CL2022001658A1 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo.
MX2021004647A (es) Formas cristalinas de moduladores de los canales de potasio.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]